Catalyst Pharmaceuticals Announces Second Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Sees 'Transformational' Next 12 Months for Catalyst Pharmaceutical (CPRX)
August 11, 2015 11:05 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and $7 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) after the company 2Q15 financials and a pipeline update, ending with $67.4M in cash.
"These resources should fully fund operations through Firdapse NDA approval and... More
Catyalyst Pharma (CPRX) Tops Q2 EPS by 2c
August 10, 2015 4:31 PM EDTCatyalyst Pharma (NASDAQ: CPRX) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.
... More